R&D Spending Showdown: GSK plc vs Viking Therapeutics, Inc.

R&D Spending: A Tale of Two Companies

In the dynamic world of pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, GSK plc and Viking Therapeutics, Inc. have showcased contrasting trajectories in their R&D investments.

GSK plc: A Steady Climb

From 2014 to 2023, GSK plc has consistently increased its R&D spending, culminating in a 80% rise over the period. This steady climb underscores GSK's commitment to innovation, with a focus on developing new therapies and maintaining its competitive edge in the global market.

Viking Therapeutics, Inc.: A Rapid Ascent

In contrast, Viking Therapeutics, Inc. has experienced a remarkable surge in R&D expenses, growing by nearly 187% from 2014 to 2023. This rapid ascent highlights Viking's aggressive strategy to expand its pipeline and establish a strong foothold in the biotech industry.

Both companies exemplify different strategies in the pharmaceutical sector, with GSK's steady approach and Viking's rapid growth offering unique insights into their future directions.